Skip to main content
BC Innovations
Feature Story

Intersection in marrow

How Gaucher's disease drugs could help multiple myeloma

By Karen Tkach, Staff Writer

An unlikely connection between Gaucher's disease and multiple myeloma has been uncovered by a U.K. group that found a common node in the pathways responsible for the bone disease symptoms that accompany both diseases. Suppression of myeloma-related bone erosion by the Gaucher's drug Zavesca miglustat suggests inhibiting sphingolipid synthesis could address the bone pathology in the cancer, and add a new angle to complement the growing list of myeloma therapies in development.

Zavesca is an inhibitor of GCS - an enzyme critical to glycosphingolipid synthesis - and is marketed by the UCB Group and Actelion Ltd. to treat Gaucher's disease and glycosphingolipid storage disorders.

Read Article
  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial